China Lifts Boeing Ban Amid US-China Trade Truce

Published 2 hours agoBA

China Lifts Boeing Ban Amid US-China Trade Truce

In a notable development, China has lifted its long-standing ban on Boeing plane deliveries, including the 737 MAX and 787 Dreamliner models. This marks the end of nearly five years of delivery suspensions and coincides with new progress in US-China trade talks.

The US and China have reached a pivotal agreement to reduce tariffs, aiming to ease trade tensions with a 90-day truce. Reuters reported that the US slashed its tariffs on Chinese goods from 145% to 30%, while China cut its tariffs on US goods to 10%. This mutual decision has generated optimism within markets, notably boosting sectors such as apparel, footwear, and travel, which are heavily dependent on the two countries' trade relations.

Boeing has strategically emphasized its commitment to the lucrative Chinese market. Boeing's China President, Alvin Liu, highlighted the exciting possibilities for collaborative efforts in the field of low-altitude logistics. Following these developments, Boeing's stock responded positively, trading at $198.53, marking an increase of $3.63 or 1.86%. The company appears set to strengthen its presence in the Chinese market amidst an improving bilateral trade environment.

Share this article

Twitter Facebook LinkedIn

Recent Articles

Honda's Profits Tumble Amid Tariffs and a Strong Yen

Honda's Profits Tumble Amid Tariffs and a Strong Yen

49 minutes agoHMC

Honda Motor Co. has reported a notable 76% drop in its operating profit for the fiscal year ending March 31, 2026. The company now forecasts an operating profit of 500 billion yen ($3.38 billion), a steep decline from the 1.21 trillion yen achieved in the previous fiscal year. The significant profit slump is primarily due to the U.S. tariffs imposed by President Donald Trump and the effects of a strengthening yen. These factors are said to overshadow the growing demand for Honda's hybrid vehicle lineup. Despite robust sales in the North American market, Reuters noted that global vehicle sales saw a 1.5% decline, reaching 2.8 million units over the first nine months of 2024, with sales in China dropping sharply by 29%. In response to these challenges, Honda has enacted cost-saving measures, including workforce reduction and suspension of operations at certain manufacturing plants. Meanwhile, Honda's stock showed a slight uptick, closing at $30.93 on May 13, 2025, reflecting a modest 1.58% increase. The company's strategic focus remains on navigating economic pressures and sustaining demand in its key markets.

China Lifts Boeing Ban Amid US-China Trade Truce

China Lifts Boeing Ban Amid US-China Trade Truce

In a notable development, China has lifted its long-standing ban on Boeing plane deliveries, including the 737 MAX and 787 Dreamliner models. This marks the end of nearly five years of delivery suspensions and coincides with new progress in US-China trade talks. The US and China have reached a pivotal agreement to reduce tariffs, aiming to ease trade tensions with a 90-day truce. Reuters reported that the US slashed its tariffs on Chinese goods from 145% to 30%, while China cut its tariffs on US goods to 10%. This mutual decision has generated optimism within markets, notably boosting sectors such as apparel, footwear, and travel, which are heavily dependent on the two countries' trade relations. Boeing has strategically emphasized its commitment to the lucrative Chinese market. Boeing's China President, Alvin Liu, highlighted the exciting possibilities for collaborative efforts in the field of low-altitude logistics. Following these developments, Boeing's stock responded positively, trading at $198.53, marking an increase of $3.63 or 1.86%. The company appears set to strengthen its presence in the Chinese market amidst an improving bilateral trade environment.

Sangamo Therapeutics Reports Narrower Losses and Strategic Gains in 2024

Sangamo Therapeutics Reports Narrower Losses and Strategic Gains in 2024

2 hours agoSGMO

Sangamo Therapeutics recently announced its financial results for the fourth quarter and full year of 2024, showing improvement in its loss figures. The company reported a net loss of $23.4 million, or $0.11 per share, for the fourth quarter of 2024, compared to a $60.3 million loss, or $0.34 per share, in the same period in 2023. For the full year, Sangamo saw a net loss of $97.9 million, or $0.49 per share, significantly better than the $257.8 million loss, or $1.48 per share, recorded in 2023. Revenue for the fourth quarter was $7.6 million, falling short of the $10.32 million predicted by analysts. The company has made strides in its strategic development goals, having entered into two major neurology license agreements in 2024. In August, Sangamo signed an agreement with Genentech for the global use of epigenetic regulation and capsid delivery for neurodegenerative diseases. Later, in December, the company inked another deal with Astellas for capsid licensing, targeting up to five neurological disease areas. Additionally, the FDA approved Sangamo's IND application for its new pain treatment candidate, ST-503, paving the way for patient enrollment by mid-2025. Looking ahead, Sangamo is focusing its strategic efforts on strengthening its neurology pipeline and advance its treatment for Fabry disease, isaralgagene civaparvovec, towards potential Accelerated Approval with the FDA. In clinical updates, the Phase 1/2 STAAR study for this treatment reported ongoing benefits and improved kidney function. Despite revenue setbacks, Sangamo's positive regulatory and strategic developments underscore its commitment to expanding treatment options for critical neurological and genetic conditions.

Telefonica Brasil's Earnings Surge Far Exceeding Expectations

Telefonica Brasil's Earnings Surge Far Exceeding Expectations

Telefonica Brasil has reported a remarkable financial performance, as evidenced by its most recent earnings release. The company posted an earnings per share (EPS) of $1.08, significantly outperforming analyst expectations, which stood at just $0.174. Additionally, Telefonica Brasil's revenue came in at an impressive $14.58 billion, far exceeding the consensus estimate of $2.48 billion, as reported by investing.com. Supporting these robust results, Telefonica Brasil's net income rose to 1.76 billion reais ($306.64 million), marking a year-over-year increase of 10.1%, as noted by marketscreener.com. The company's mobile services revenue grew by 7.0% to 9.2 billion reais, while its fixed revenue saw an 8.0% uptick, driven by Fiber-to-the-Home (FTTH), and Corporate Data, ICT, and Digital Services. The company's EBITDA also experienced a healthy growth of 7.8%, reaching 6.2 billion reais with a margin of 42.5%. Meanwhile, capital expenditure rose 2.3% from the previous year, totaling 9.166 billion reais. Telefonica Brasil's focus on shareholder remuneration was evident, distributing 5.845 billion reais, which represents a 22.1% increase from the previous year, equating to a payout of 105.3% of net income. These figures reflect the company's strategic focus on maintaining financial stability while enhancing shareholder value.